Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,061 people get ARRY articles and Market Currents by email alert.
Get email alerts on ARRY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 15, 2013)
-
-
-
-
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 6, 2013)
-
PR Newswire (Apr 29, 2013)
-
-
PR Newswire (Apr 4, 2013)
-
-
Piper Jaffray Likes Array, Should You?Brian L. Wilson • Mon, Mar 25 -
PR Newswire (Mar 21, 2013)
-
PR Newswire (Feb 26, 2013)
-
-
-
-
-
-
-
Piper Jaffray Likes Array, Should You?Brian L. Wilson • Mon, Mar 25
-
-
-
-
-
Array BioPharma's Cancer Deal Expands Its CoffersM. E. Garza • Tue, Aug 9, 2011
-
Bottom Bounce for Array BioPharmaM. E. Garza • Wed, Jun 29, 2011
-
Array Biopharma: A Wall Street AnomalyOhad Hammer • Mon, Oct 4, 2010
-
-
-
-
-
-
-
-
5 Small Cap Stocks Under $5 With Short CoveringKapitall • Wed, Oct 24, 2012 -
-
-
-
-
-
-
-
Monday Options Recap: Cisco, Intel Risk ReversalFrederic Ruffy • Mon, Apr 9, 2012 -
-
-
-
-
Array BioPharma Inc. F4Q10 (Qtr End 06/30/10) Earnings Call TranscriptTue, Aug 10, 2010
-
Array BioPharma F2Q09 (Qtr End 12/31/08) Earnings Call TranscriptTue, Feb 3, 2009
-
Array BioPharma F1Q09 (Qtr End 09/30/08) Earnings Call TranscriptTue, Nov 4, 2008
-
Array BioPharma, Inc., Q3 Earnings Call TranscriptTue, May 6, 2008
-
Array BioPharma Inc. Q2 2008 Earnings Call Transcript.Tue, Feb 5, 2008
-
PR Newswire (May 15, 2013)
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 6, 2013)
-
PR Newswire (Apr 29, 2013)
-
PR Newswire (Apr 4, 2013)
-
PR Newswire (Mar 21, 2013)
-
PR Newswire (Feb 26, 2013)
-
PR Newswire (Feb 8, 2013)
-
PR Newswire (Feb 4, 2013)
-
PR Newswire (Jan 29, 2013)
-
PR Newswire (Dec 27, 2012)
-
Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology MeetingPR Newswire (Dec 10, 2012)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 15, 2012)
-
at MarketWatch.com (Nov 9, 2012)
-
PR Newswire (Nov 9, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Nov 8, 2012)
ARRY vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
- Monday, May 6, 4:07 PM Array Biopharma (ARRY): Q1 EPS of -$0.19 misses by $0.05. Revenue of $10M misses by $4.54M. (PR) Comment! [Earnings, Breaking News]
- Monday, May 6, 12:10 AM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
- Sunday, May 5, 5:35 PM Notable earnings after Monday’s close: ALNY, AMTG, APC, ARRY, BSFT, CECO, CHUY, DPM, ENOC, EOG, FSLR, FST, FTR, GDP, GSM, GWAY, HIMX, HOLX, LGCY, MELI, MKTG, MMLP, MR, NOG, NRP, OTTR, PAA, PEGA, PNG, RKUS, SGY, SMG, SNTS, STAG, VNO, WMS Comment! [Earnings]
- Thursday, April 4, 8:53 AM Array BioPharma's (ARRY +2.25%) ARRY-520 drug for multiple myeloma showed encouraging clinical activity in two trials of patients who had received heavy previous treatments and had "limited therapeutic options." The median survival rates was 19 months and the overall response rate 16%, similar to other recently approved products. ARRY-520 was also well tolerated. (PR) Comment! [Healthcare]
- Wednesday, March 27, 6:13 PM Array Biopharma (ARRY) says it's entered into a sales agreement for an at-the-market share offering with Cantor Fitzgerald. Subject to the terms and conditions, ARRY] may from time to time issue and sell through Cantor up to $75M in stock. Shares -5% AH. Comment! [On the Move, Healthcare]
-
Wednesday, March 27, 5:49 PM
After-hours top gainers, as of 5:15 p.m.: GBX +3%. GNW +3%. LCC +3%. MATX +1.4%. SU +1.1%.
After-hours top losers: ARRY -12%. RHT -9%. FIVE -7%. ESI -6%. PVH -5%. Comment! [On the Move] - Monday, March 25, 10:52 AM Array BioPharma (ARRY +11%) gets a big boost from an upgrade to Overweight at Piper Jaffray this morning, pushing the stock near a 5-month high. Piper says the company has a host of potentially positive study data due out later this year, and several partnering opportunities in FY13 that could bring in non-dilutive funding. This is encouraging, as the company already finished 2012 with $110M of cash, which the firm estimates would get ARRY through mid-2014. Comment! [Healthcare, On the Move]
- Monday, February 4, 5:15 PM More on Array Biopharma (ARRY): Q2 beats as per share losses come in less-than-expected. CEO Ron Squarer notes strong progress across its pipeline, with Novartis saying it's set to begin Phase 3 trials of MEK162, and AstraZeneca set to start Phase 3 trials with selumetinib in non-small cell lung cancer during the second half of 2013. Comment! [Healthcare, Earnings]
- Monday, February 4, 4:53 PM Array Biopharma (ARRY): FQ2 EPS of -$0.1 beats by $0.04. Revenue of $18.4M beats by $1.88M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, February 4, 12:10 AM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
- Sunday, February 3, 5:35 PM Notable earnings after Monday’s close: ACLS, APC, APKT, ARRY, BIDU, EW, GGP, GILD, HI, HIG, HOLX, LEG, LIFE, MDU, MKL, SIMO, SWI, YUM Comment! [Earnings]
-
Wednesday, November 21, 2012, 5:39 PM
After-hours top gainers, as of 5:15 p.m.: IMGN +7.1%. SHLD +4.2%. ARRY +3.4%. IDIX +3.0%. VRTX +2.5%.
After-hours top losers: MRGE -9.0%. CVGI -7.1%. GORO -6.6%. HW -6.3%. QLIK -4.5%. 2 Comments [On the Move] - Friday, November 9, 2012, 10:39 AM Drug developer Array BioPharma (ARRY -12.3%) slides after pricing an 18M share secondary offering at $3.65 per share, a 10% discount to yesterday's close. The company had 95.4M shares outstanding as of October, which would make the sale nearly a 19% dilution to its float. Comment! [Healthcare, On the Move]
-
Friday, November 9, 2012, 9:10 AM
Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move] - Friday, August 31, 2012, 4:15 PM Array BioPharma (ARRY) announces that Francis Bullock, Ph.D., and Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of Directors and that David Snitman, Ph.D., intends to resign from the Board. Comment! [Healthcare]
-
Ryan Mallory
My Swing Trading Watch-List for Long Setups | $LULU $KWK $AEGR $EW $ARRY and others. http://bit.ly/RCo0Zb - View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting
-
Roy Manning III
ARRY is a good buy. Expecting $20 million in milestone payments by end of year. Payments from partners keep this stock profitable. - View all 0 replies
-
whitehead1
I am buying ARRY before earning. I think it has very good upside after earning report for a trade. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 2 replies
-
-
johnjail: nice pipeline and nice last quarter :) but I didn't find the cash they have and the burn rate. at that price seems to be interesting